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A significant number of patients undergoing non-cardiac surgery are at risk of cardiac
complications including myocardial infarction and cardiac-related death. There is still
ongoing debate about the most appropriate management when faced with a pre-operative
patient with coronary artery disease. We present the case of a 70-year old male with
significant coronary artery disease and left ventricular systolic dysfunction who
unfortunately was also diagnosed with a non-small cell lung cancer and required surgical
intervention. The management with the use of the intra-aortic balloon pump (IABP) for
cardio-protection is discussed.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Annually, worldwide, an estimated 0.5% (500,000) of the 100
million adults undergoing non-cardiac surgery dies during
the peri-operative phase due to cardiac disease1 with 1.1
million patients experiencing a myocardial infarction (MI).2
Although the patho-physiology of peri-operative MI is not
entirely clear, coronary plaque rupture and thrombus
formation during the hyper-coagulable status of the peri-
operative period is responsible in 50% of all fatal MI while inElsevier Ltd. All rights reserved.
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l.com (H. Luckraz).the remaining 50% there is a sustained oxygen supply/
demand mismatch.3
We describe the use of the intra-aortic balloon counter-
pulsation therapy (IABP) as a management strategy for a
patient with ischaemic heart disease undergoing lung cancer
surgery.Case report
A 70-year old male was referred for coronary artery bypass
surgery (CABG). His risk factors included hypertension,
hypercholesterolemia and 35-pack year current smoker.
Angiography confirmed triple vessel coronary artery disease
(CAD) with impaired left ventricular (LV) function (ejection
fraction: 40%). Pre-operative, chest radiography revealed
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CT scan confirmed a 20 14mm nodule in posterior segment
in right upper lobe abutting the fissure as well as right lower
para-tracheal lymphadenopathy. PET scan staged the lesion
as T1N2M0 disease.
Attempts at confirming the staging by trans-bronchial fine
needle aspiration were unsuccessful. He was therefore
scheduled for mediastinoscopy and biopsy of para-tracheal
lymph nodes and should these be negative on frozen section,
then to proceed to lobectomy within the same anaesthetic.
The options for cardio-protection included beta blockade,
revascularisation pre-biopsy or cardio-protection with an
intra-aortic balloon pump (IABP). Due to the significant
impairment of LV function as well as coronary artery disease,
it was felt that beta-blockade alone might not provide
adequate cardio-protection. On the other hand, this patient
could potentially have stage IIIB lung cancer and hence
revascularization with CABG would be inappropriate. PCI
could have been an option but only bare-metal stents would
be indicated and he would have been at a higher risk of
myocardial injury for the subsequent 6 weeks with risk of
disease (lung cancer) progression.
IABP was chosen after assessing the above risks and
benefits and was inserted 12 h pre-op.
Unfortunately frozen section confirmed N2 disease (sta-
tion 4R). The patient underwent an uneventful procedure.
The IABP was removed 12 h postoperatively. He was
discharged home the evening after IABP removal. He was
then reviewed the next day by the oncologist to discuss and
plan further therapy.Discussion
Currently, there is no established evidence to support the
management strategies in patients at risk of myocardial
damage and who are undergoing non-cardiac surgery.
Surgeons are guided by AHA/ACC guidelines.4 The arma-
mentarium available for peri-operative cardio-protection
includes medical optimization with beta-blockers and
coronary artery revascularisation either by percutaneous
coronary intervention (PCI) or CABG.
These assess the risks of myocardial injury in terms of the
patient characteristics and surgical procedure to be under-
taken.
The patient described above, was classed as being at high
risk due to triple vessel CAD in association with impaired LV,
his age and other co-morbidities such as hypertension and
current smoker.
The initial thought was to optimize his beta-blockade
therapy. However, the evidence for this strategy is still
under debate. The benefits of beta-blockade were con-
firmed in the meta-analysis by Auerbach and Goldman.5
They analyzed the results of five studies (n ¼ 685 patients)
and reported that an episode of significant myocardial
ischaemia is avoided for every sixth patient treated with a
B-blocker compared to placebo in patients undergoing non-
cardiac surgery. Moreover, a database review by Lindenauer
et al.6 showed that, in a group of over 500,000 patients,
peri-operative beta-blocker therapy was associated with a
reduced risk of in-hospital death among high-risk, but not
low-risk, patients undergoing major non-cardiac surgery.However, the benefits of peri-operative B-blockers remain
uncertain as published in another meta-analysis recently.7
Review of the effects of B-blockers from 22 studies (nearly
2500 patients) did not show any significant reduction in
cardiovascular mortality, non-fatal myocardial infarction,
and non-fatal cardiac events.
The recommendation from the AHA/ACC in terms of
coronary revascularization by CABG is relatively straight
forward.4 If a patient, is not a surgical candidate for CABG
on either prognostic or symptomatic grounds,8 then surgical
coronary revascularisation is not indicated irrespective of
the need for non-cardiac surgery.4,8 However, in the case
that is described above, his initial referral was for CABG but
the lung lesion was picked up pre-operatively. However, the
lung pathology could be a Stage IIIB tumour in which case
CABG would not be appropriate.
The use of intra-aortic counter-pulsation adds to the
management armamentarium for this category of patients.
IABP insertion is associated with a very low morbidity
(around 3%) and mortality (o1%) in our unit. It provides
effective myocardial protection by improving coronary
artery blood flow during the diastolic augmentation and
reduces myocardial oxygen demand in systole by reducing
the afterload. The drawback of IABP is that it does not
reduce tachycardic episodes during the peri-operative phase
and that they do carry an increased risk of morbidity
especially in non-expert hands. However, IABP can be used
in conjunction with B-blockers for optimal benefit.Conflict of interest statement
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